AELIS FARMA Revenue and Competitors
Estimated Revenue & Valuation
- AELIS FARMA's estimated annual revenue is currently $5.9M per year.
- AELIS FARMA's estimated revenue per employee is $155,000
Employee Data
- AELIS FARMA has 38 Employees.
- AELIS FARMA grew their employee count by 12% last year.
AELIS FARMA's People
| Name | Title | Email/Phone |
|---|
AELIS FARMA Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $99.4M | 458 | 40% | N/A | N/A |
#2 | $20.6M | 133 | 22% | N/A | N/A |
#3 | $156.1M | 146 | -70% | $145M | N/A |
#4 | $3.5M | 45 | -25% | $150M | N/A |
#5 | $1.6M | 21 | 0% | $459.5M | N/A |
#6 | $67.3M | 310 | 16% | $180.7M | N/A |
#7 | $8.5M | 55 | -2% | N/A | N/A |
#8 | $256.3M | 1025 | 9% | $168.5M | N/A |
#9 | $2.8M | 18 | -33% | N/A | N/A |
#10 | $9.1M | 59 | -9% | N/A | N/A |
What Is AELIS FARMA?
Aelis Farma mission: Develop the therapeutic potential of CB1-SSi CB1 Signaling Specific inhibitors (CB1-SSi) are a proprietary new pharmacological class never tested in humans before that open a new frontier in pharmacology. CB1-SSi have a unique mechanism of action CB1-SSi are new molecular entities (NME) that mimicking a natural defense mechanism of the brain (Science 2014). CB1-SSi do not block, like available antagonists, all the cellular activities of a receptor. CB1-SSi correct selectively the cellular activity hyperactivated in the pathological state. CB1-SSi do not modifying normal physiology or behavior and have no identifiable toxicity and side effects. CB1-SSi have broad therapeutic targets: CB1-SSi modify the principal target of cannabinoid therapeutics, the CB1 receptor, which is involved in a large spectrum of diseases of the central nervous system and peripheral organs.
keywords:N/A
N/A
Total Funding
38
Number of Employees
$5.9M
Revenue (est)
12%
Employee Growth %
N/A
Valuation
N/A
Accelerator
AELIS FARMA News
Aelis Farma (ISIN : FR0014007ZB4 Mnémonique : AELIS), société biopharmaceutique au stade clinique spécialisée dans le développement de...
Accord d'envergure, entrée en Bourse La biotech bordelaise Aelis Farma poursuit, ces derniers mois, une dynamique exemplaire. Au printemps 2021...
Founded in 2013, Aelis Farma is a biopharmaceutical company that is developing a new class of drugs, the Signaling Specific inhibitors of the...
Other Companies in bordeaux cedex
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $89.7M | 326 | 28% | N/A |